Drugs interactions for Gammagard Liquid®
- 0 Major drug interactions
- 1 Moderate drug interactions (including ingredients like Pozelimab)
- 156 Minor drug interactions (including ingredients like Adalimumab, Aducanumab, Alemtuzumab)
157 interactions for Gammagard Liquid®The serum concentration of Pozelimab can be decreased when it is combined with Human immunoglobulin G.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Adalimumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Aducanumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Alemtuzumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Alirocumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Amivantamab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Anifrolumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ansuvimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Anthrax immune globulin human.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antilymphocyte immunoglobulin (horse).The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antithymocyte immunoglobulin (rabbit).The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Asfotase alfa.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Atezolizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Atoltivimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Avelumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Axatilimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bamlanivimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Basiliximab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Belimumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Benralizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bevacizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bezlotoxumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bimekizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Blinatumomab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Brentuximab vedotin.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Brodalumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Brolucizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Burosumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Canakinumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Caplacizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Cemiplimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Certolizumab pegol.The risk or severity of adverse effects can be increased when Cetuximab is combined with Human immunoglobulin G.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Cilgavimab.Conjugated estrogens may increase the thrombogenic activities of Human immunoglobulin G.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Crovalimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Daratumumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Denosumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Digoxin Immune Fab (Ovine).The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dinutuximab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Donanemab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dostarlimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dulaglutide.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dupilumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Durvalumab.The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Human immunoglobulin G.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eculizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eflapegrastim.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eftrenonacog alfa.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Elotuzumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Emapalumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Emicizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eptinezumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Erenumab.Esterified estrogens may increase the thrombogenic activities of Human immunoglobulin G.Estetrol may increase the thrombogenic activities of Human immunoglobulin G.Estradiol may increase the thrombogenic activities of Human immunoglobulin G.Estradiol acetate may increase the thrombogenic activities of Human immunoglobulin G.Estradiol cypionate may increase the thrombogenic activities of Human immunoglobulin G.Estradiol valerate may increase the thrombogenic activities of Human immunoglobulin G.Estriol may increase the thrombogenic activities of Human immunoglobulin G.Estrone sulfate may increase the thrombogenic activities of Human immunoglobulin G.Ethinylestradiol may increase the thrombogenic activities of Human immunoglobulin G.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Evolocumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fanolesomab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fremanezumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gemtuzumab ozogamicin.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Glofitamab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Golimumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Guselkumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Hepatitis B immune globulin.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Human cytomegalovirus immune globulin.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Human Rho(D) immune globulin.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Human varicella-zoster immune globulin.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ibalizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ibritumomab tiuxetan.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Idarucizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Inebilizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Infliximab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Inotuzumab ozogamicin.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ipilimumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Isatuximab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ixekizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lanadelumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lebrikizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lecanemab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Loncastuximab tesirine.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Maftivimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Margetuximab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Marstacimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mepolizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mirvetuximab Soravtansine.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mogamulizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mosunetuzumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Natalizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Necitumumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Nemolizumab.The serum concentration of Human immunoglobulin G can be decreased when it is combined with Nipocalimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Nivolumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Obiltoxaximab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Obinutuzumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ocrelizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Odesivimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ofatumumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Olaratumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Omalizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Palivizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Panitumumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pembrolizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Penpulimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pertuzumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Polatuzumab vedotin.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ramucirumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ranibizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ravulizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Raxibacumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Relatlimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Reslizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Risankizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rituximab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Romosozumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rozanolixizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sacituzumab govitecan.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sarilumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Secukinumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Siltuximab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sotatercept.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sotrovimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Spesolimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sutimlimab.Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Human immunoglobulin G.Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Human immunoglobulin G.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tafasitamab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Telisotuzumab vedotin.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Teplizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Teprotumumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tetanus immune globulin, human.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tezepelumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tildrakizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tislelizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tisotumab vedotin.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tixagevimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tocilizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Toripalimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tralokinumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Trastuzumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Trastuzumab deruxtecan.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Trastuzumab emtansine.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tremelimumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ublituximab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ustekinumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vedolizumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vilobelimab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Zanidatamab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Zenocutuzumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Zolbetuximab.
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Gammagard Liquid®.
Pozelimab
Adalimumab
Aducanumab
Alemtuzumab
Alirocumab
Amivantamab
Anifrolumab
Ansuvimab
Anthrax immune globulin human
Antilymphocyte immunoglobulin (horse)
Antithymocyte immunoglobulin (rabbit)
Asfotase alfa
Atezolizumab
Atoltivimab
Avelumab
Axatilimab
Bamlanivimab
Basiliximab
Belimumab
Benralizumab
Bevacizumab
Bezlotoxumab
Bimekizumab
Blinatumomab
Brentuximab vedotin
Brodalumab
Brolucizumab
Burosumab
Canakinumab
Caplacizumab
Cemiplimab
Certolizumab pegol
Cetuximab
Cilgavimab
Conjugated estrogens
Crovalimab
Daratumumab
Denosumab
Digoxin Immune Fab (Ovine)
Dinutuximab
Donanemab
Dostarlimab
Dulaglutide
Dupilumab
Durvalumab
Ebola Zaire vaccine (live, attenuated)
Eculizumab
Eflapegrastim
Eftrenonacog alfa
Elotuzumab
Emapalumab
Emicizumab
Eptinezumab
Erenumab
Esterified estrogens
Estetrol
Estradiol
Estradiol acetate
Estradiol cypionate
Estradiol valerate
Estriol
Estrone sulfate
Ethinylestradiol
Evolocumab
Fanolesomab
Fremanezumab
Galcanezumab
Gemtuzumab ozogamicin
Glofitamab
Golimumab
Guselkumab
Hepatitis B immune globulin
Human cytomegalovirus immune globulin
Human Rho(D) immune globulin
Human varicella-zoster immune globulin
Ibalizumab
Ibritumomab tiuxetan
Idarucizumab
Inebilizumab
Infliximab
Inotuzumab ozogamicin
Ipilimumab
Isatuximab
Ixekizumab
Lanadelumab
Lebrikizumab
Lecanemab
Loncastuximab tesirine
Maftivimab
Margetuximab
Marstacimab
Mepolizumab
Mirvetuximab soravtansine
Mogamulizumab
Mosunetuzumab
Natalizumab
Necitumumab
Nemolizumab
Nipocalimab
Nivolumab
Obiltoxaximab
Obinutuzumab
Ocrelizumab
Odesivimab
Ofatumumab
Olaratumab
Omalizumab
Palivizumab
Panitumumab
Pembrolizumab
Penpulimab
Pertuzumab
Polatuzumab vedotin
Ramucirumab
Ranibizumab
Ravulizumab
Raxibacumab
Relatlimab
Reslizumab
Risankizumab
Rituximab
Romosozumab
Rozanolixizumab
Sacituzumab govitecan
Sarilumab
Secukinumab
Siltuximab
Sotatercept
Sotrovimab
Spesolimab
Sutimlimab
Synthetic Conjugated Estrogens, A
Synthetic Conjugated Estrogens, B
Tafasitamab
Telisotuzumab vedotin
Teplizumab
Teprotumumab
Tetanus immune globulin, human
Tezepelumab
Tildrakizumab
Tislelizumab
Tisotumab vedotin
Tixagevimab
Tocilizumab
Toripalimab
Tralokinumab
Trastuzumab
Trastuzumab deruxtecan
Trastuzumab emtansine
Tremelimumab
Ublituximab
Ustekinumab
Vedolizumab
Vilobelimab
Zanidatamab
Zenocutuzumab
Zolbetuximab